Sagimet clears the FDA gate—but the real acne test is still ahead

The direction was expected; the regulatory clearance is the new information. Sagimet had already said it planned to file the acne IND in mid-2026 and begin a U.S. registrational Phase 3 study in the second half of 2026, conditional on FDA clearance.

The filing removes the main near-term execution risk. The FDA cleared the IND and issued a “Study May Proceed” letter for denifanstat in moderate-to-severe acne, allowing the Phase 3 trial to move forward. (Item 8.01, Other Events)

This is a development milestone, not a clinical readout. The filing provides no new efficacy, safety, enrollment, trial-design, or launch-timing data. The benefit versus expectations is therefore limited to regulatory de-risking: the company has cleared the gate it previously identified, but the trial’s outcome—and the larger commercial case—remain unresolved.